Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry

Publisher： John Wiley & Sons Inc

E-ISSN： 1445-5994|46|9|1054-1062

ISSN： 1444-0903

Source： INTERNAL MEDICINE JOURNAL, Vol.46, Iss.9, 2016-09, pp. : 1054-1062

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Improvement in quality of life with omalizumab in patients with severe allergic asthma

By Chipps Bradley   Buhl Roland   Beeh Kai-Michael   Fox Howard   Thomas Karen   Reisner Colin  

Current Medical Research and Opinion, Vol. 22, Iss. 11, 2006-11 ,pp. : 2201-2208

Informa Healthcare

Access to resources Recommend Favorite

Omalizumab for Severe Allergic Asthma: 7 Years and Open Questions

By  

Respiration, Vol. 88, Iss. 2, 2014-05 ,pp. : 158-161

Karger

Access to resources Recommend Favorite

Omalizumab could be effective in children with severe eosinophilic non‐allergic asthma

By  

PEDIATRIC ALLERGY AND IMMUNOLOGY, Vol. 29, Iss. 1, 2018-02 ,pp. : 90-93

John Wiley & Sons Inc

Access to resources Recommend Favorite

Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients

By Siergiejko Zenon   ŚŚwiebocka Ewa   Smith Nicola   Peckitt Clare   Leo Jo   Peachey Guy   Maykut Robert  

Current Medical Research and Opinion, Vol. 27, Iss. 11, 2011-11 ,pp. : 2223-2228

Informa Healthcare

Access to resources Recommend Favorite

Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma

By Grossman H.L.   Schlender Amory   Alperin Peter   Stanley Elizabeth L.   Zhang Jie  

Current Medical Research and Opinion, Vol. 26, Iss. 12, 2010-12 ,pp. : 2779-2793

Informa Healthcare

Access to resources Recommend Favorite